source
- Sarepta receives FDA decision deadline for exon-skipping therapies, appoints Anna Protopapas as Flare CEOThe U.S. Food and Drug Administration has set a deadline for a decision on Sarepta Therapeutics' exon‑skipping drug program, with the agency expected to rule by the end of February. The timing is…
- FDA gene and cell therapy review office loses acting director Vijay KumarVijay Kumar has announced he will step down from his role as acting director of the Office of Gene and Cell Therapy Reviews within the FDA's Center for Biologics Evaluation and Research. Karim Mik…